Strategy & Management

Magazine articles on business strategy, management and leadership.

Old Articles: <Older 15511-15520 Newer>

Pharmaceutical Executive August 1, 2012	Piramal Pivots for Growth Western drug makers face an unlikely challenge from India's Piramal Healthcare, which has divested its big stake in branded generics for the risky embrace of new drug innovation.
Pharmaceutical Executive August 1, 2012 Ben Comer	Compliance Kulture: The Facts Behind GSK's CIA Big Pharma talks a lot about changing its business model to one that prioritizes quality and value over quantity and waste. How do you judge a sales rep's performance if not on how much she sells?
Pharmaceutical Executive August 1, 2012 Stan Bernard	Creallaborations: Pharma Starts Thinking Outside the Pill Box Creative non-pharmaceutical partnerships can offer innovators unique capabilities against the competition in a new era where challenges to market leadership are coming from every direction.
Pharmaceutical Executive August 1, 2012 Andrea Sobrio	Innovative Contracting: What is the Verdict? Industry is finding it harder to secure market access and payer uptake for new products. Innovative contracting may offer a solution. Is it working?
Pharmaceutical Executive August 1, 2012 Carol Ann Williams	Data Exclusivity: Making the Case As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine.
Pharmaceutical Executive August 1, 2012 Julian Upton	Brand Building -- Not! As a drug company promoting a drug free Olympiad, GSK wins our gold hands down for finally putting the industry's best face forward on the last frontier of advertising and the TV sets of Europe.
Pharmaceutical Executive August 1, 2012 Wendy Balter	New Approaches to Medical Education Planning Promotional medical education planning used to be able to focus on the science first, without much consideration for delivery channels. Now technology expertise and channel considerations demand an equal share in up-front planning.
Pharmaceutical Executive August 1, 2012 William Looney	The Phrase that Plays The FDA is creatively applying regulatory fiat to force fundamental changes in company culture.
HBS Working Knowledge August 13, 2012 Carmen Nobel	When Good Incentives Lead to Bad Decisions New research explores how various compensation incentives affect lending decisions among bank loan officers.
HBS Working Knowledge August 6, 2012 Michael Blanding	Strategic Intelligence: Adapt or Die In his new book, Strategic IQ: Creating Smarter Corporations, Harvard Business School Professor of Management Practice John R. Wells explains why adapting to changing circumstances isn't only smart, it's also a matter of survival.
<Older 15511-15520 Newer> Return to current articles.